Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Skin Diseases

Skin Neoplasms

Breast Diseases

All Drugs and Chemicals

Somatostatin

A group of female volunteers infected with breast cancer will receive topical Quantum dots in different dosage forms.

A group of female volunteers infected with breast cancer will receive placebo cream as a negative control.

The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.

Quantum dots coated with veldoreotide

The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.

Topical approved placebo

Ahmed AH Abdellatif, PhD

Ahmed AH Abdellatif, Ph.D.

Breast cancer is a communal malignant disease between Saudi females, with a popularity of 21.8%. Since binding to somatostatin receptors (SSTR) induces no immunogenicity in vivo, somatostatin analog (veldoreotide) (VELD) may be suitable for delivering anti-cancer drugs to target and bioimaging the cancer cells. This work aimed to deliver CdS/ZnS core-shell type quantum dots with carboxylic acid-functionalized (QDs-COOH) which is bioimaging and anticancer nanoparticles decorated VELD as SSTR agonist with anti-cancer activity in the form of topical cream to be deposited deep in the breast periphery.

QDs-COOH will be conjugated to the N terminal of phenylalanine of VELD when the reaction proceeded at pH 7. Topical cream will be adapted to deliver the conjugated system for maximum deposition through breast cancer cells using emulsion technology. The formulated nanoparticles and cream will be characterized for size using dynamic light scattering, drug-polymer interaction using FTIR, and morphology using SEM. Cellular uptake, permeability and cell viability study of the successful system of interest will be studied in cell culture models using different breast cell lines. Moreover, the in vivo study will also proceed on rats induced breast cancer. Finally, the nanoparticles loaded in a topical cream will be applied with clinical trial approvement on the human breast cancer for bioimaging and treating breast cancer. This work is to present a novel formulation for treatment and bioimaging of breast cancer which can deliver safely to the patients in a high dose to the affected tumor cells.

Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer

Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer

The authors could not decide until now a plan to make individual participant data (IPD) available to other researchers.

QDs-VELD have anticancer activity. This study will be determined by measuring the growth inhibition of anticancer activity for QDs-VELD.

The bioimaging effect for scintigraphy of breast cancer.

Stability test will be studied for dosage forms. The test will carried out by standing the products on shelf life for three months. The stability test will be recorded using high performance liquid chromatography each thee days.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer	NCT04138342	Breast Cancer Skin Cancer Skin Diseases	Quantum dots co... Topical approve...	25 Years - 60 Years	Al-Azhar University
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer	NCT04138342	Breast Cancer Skin Cancer Skin Diseases	Quantum dots co... Topical approve...	25 Years - 60 Years	Al-Azhar University

Spots Global Cancer Trial Database for quantum dots coated with veldoreotide